Develop studies to improve treatment of non-metastatic prostate cancer, with a particular emphasis on surgical and minimally-invasive interventions.
We will achieve this by developing and supporting studies that aim to improve the therapeutic ratio of surgical interventions and radiotherapy through a reduction in side-effects, whilst maintaining effective cancer control, for patients with non-metastatic prostate cancer who require treatment.
New approaches to delivery of surgery using frozen sections, for instance in the Neurosafe randomised control trial, was supported by the NCRI Prostate Group and over the next five years further innovations in surgery, such as the evaluation of Retzius sparing radical prostatectomy and precision prostatectomy, will be supported through evaluation in comparative studies ideally using novel trial designs to ensure recruitment is efficient.